

# Experimentally evolved *Staphylococcus aureus* shows increased survival in the presence of *Pseudomonas aeruginosa* by acquiring mutations in the amino acid transporter, GltT

Ashley M. Alexander<sup>1,2,3</sup>, Justin M. Luu<sup>3,4</sup>, Vishnu Raghuram<sup>2,3,4</sup>, Giulia Bottacin<sup>5</sup>, Simon van Vliet<sup>5,6</sup>, Timothy D. Read<sup>2</sup> and Joanna B. Goldberg<sup>3,\*</sup>

#### Abstract

When cultured together under standard laboratory conditions *Pseudomonas aeruginosa* has been shown to be an effective inhibitor of *Staphylococcus aureus*. However, *P. aeruginosa* and *S. aureus* are commonly observed in coinfections of individuals with cystic fibrosis (CF) and in chronic wounds. Previous work from our group revealed that *S. aureus* isolates from CF infections are able to persist in the presence of *P. aeruginosa* strain PAO1 with a range of tolerances with some isolates being eliminated entirely and others maintaining large populations. In this study, we designed a serial transfer, evolution experiment to identify mutations that allow *S. aureus* to survive in the presence of *P. aeruginosa*. Using *S. aureus* USA300 JE2 as our ancestral strain, populations of *S. aureus* were repeatedly cocultured with fresh *P. aeruginosa* PAO1. After eight coculture periods, *S. aureus* populations that survived better in the presence of PAO1 were observed. We found two independent mutations in the highly conserved *S. aureus* aspartate transporter, *gltT*, that were unique to evolved *P. aeruginosa*tolerant isolates. Subsequent phenotypic testing demonstrated that *gltT* mutants have reduced uptake of glutamate and outcompeted wild-type *S. aureus* when glutamate was absent from chemically defined media. These findings together demonstrate that the presence of *P. aeruginosa* exerts selective pressure on *S. aureus* to alter its uptake and metabolism of key amino acids when the two are cultured together.

## **INTRODUCTION**

Diverse microbial communities may alter infection environments through interspecific interactions that involve metabolic exchange, altered adaptive trajectories of pathogens or symbionts, and changing antibiotic susceptibilities [[1–5](#page-12-0)]. In the case of chronic infections, multiple opportunistic pathogens can coexist in their shared host environment for many generations, exerting their own respective selective pressures on one another [\[6](#page-12-1)]. Pairwise interactions between the opportunistic pathogens, *Staphylococcus aureus* and *Pseudomonas aeruginosa* have become a topic of interest to microbiologists, both for their importance in chronic wound infections and respiratory infections associated with the genetic disease cystic fibrosis (CF), as well as their potential to serve as a model system for studying pathogen coevolution [[7, 8\]](#page-12-2).

Previous studies have demonstrated that the laboratory strains, *S. aureus* USA300 JE2 and *P. aeruginosa* PAO1, interact competitively when cultured together and that those interactions are greatly influenced by factors such as alginate and quinolone production by PAO1 [[9–11](#page-12-3)]. Additionally, it has been observed that JE2 can adapt to secreted factors present in PAO1 supernatant in short-term evolution experiments [[12\]](#page-12-4). Other studies have shown that adaptations to specific

\*Correspondence: Joanna B. Goldberg, joanna.goldberg@emory.edu

NCBI accession number: PRJNA1055168.

 $\odot$   $\odot$ This is an open-access article distributed under the terms of the Creative Commons Attribution License.

Received 03 January 2024; Accepted 20 February 2024; Published 01 March 2024

Author affiliations: <sup>1</sup>Population Biology, Ecology, and Evolution Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, Georgia, USA; <sup>2</sup>Division of Infectious Diseases and Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA; <sup>3</sup>Department of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, Georgia, USA; <sup>4</sup>Microbiology and Molecular Genetics Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, Georgia, USA; <sup>5</sup>Biozentrum, University of Basel, Spitalstrasse 41,4056 Basel, Switzerland; <sup>6</sup>Department of Fundamental Microbiology, University of Lausanne, Quartier Unil-Sorge, 1015 Lausanne, Switzerland.

Keywords: amino acid metabolism; cystic fibrosis; experimental evolution; interspecies competition; *Pseudomonas aeruginosa*; *Staphylococcus aureus*.

Three supplementary figures, two supplementary tables and one supplementary methods are available with the online version of this article. 001445 © 2024 The Authors

compounds such as 2-heptyl-4-hydroxyquinoline-N-oxide (HQNO) and pyocyanin may impact the antibiotic resistance profiles of either species [\[9, 13–15\]](#page-12-3). Strain background is also a determining factor in interactions between these two species. Clinical isolates of *S. aureus* taken from CF-associated infections have been shown to have a range of tolerances to PAO1. Previous work by our group found that sensitive *S. aureus* isolates experienced as much as a six-fold decrease in recovered colony-forming units (CFUs) after coculture, while others maintained most of their population, experiencing less than a two-fold decrease in population size [[16\]](#page-12-5). Additionally, other groups have found that *S. aureus* isolated from coinfections with *P. aeruginosa* have acquired mutations that reduce the efficiency of fermentative metabolism, polysaccharide production, and toxin excretion [[9, 17](#page-12-3)]. While many factors have been identified as influential in *S. aureus-P. aeruginosa* interactions, it is unclear how an evolving *S. aureus* population would adapt to the presence of *P. aeruginosa* in a shared environment.

In this study, we sought to gain a greater understanding for which *S. aureus* traits are under strong selective pressure when *P. aeruginosa* is introduced. To isolate and study specific genes involved in *S. aureus'* adaptation to *P. aeruginosa,* we performed our studies with the standard laboratory strains, *S. aureus* JE2 and *P. aeruginosa* PAO1. In a serial transfer evolution experiment, we showed that *S. aureus* populations could adapt to the negative selective pressures presented by *P. aeruginosa* under laboratory conditions. We found that rather than adapting to secreted toxins or contact-dependent killing, *S. aureus* improved its survival in the presence of *P. aeruginosa* by halting its uptake of aspartate through the disruption of its singular aspartate transporter, *gltT* [[18\]](#page-12-6). We hypothesize that loss of function of this membrane transporter results in *S. aureus* becoming more resilient to fluctuations in nutrient availability caused by the presence of *P. aeruginosa* in its environment. These results are surprising given that *P. aeruginosa* has other well-characterized mechanisms for directly inhibiting *S. aureus* in its environment. However, our findings suggest that optimizing amino acid metabolism is a potential pathway for adaptation for *S. aureus* that co-occurs with *P. aeruginosa*.

# **METHODS**

### **Bacterial strains**

Bacterial strains and plasmids used in this study are included in ([Table 1](#page-1-0)). A JE2 *gltT* mutant (*SAUSA300\_2329*) was obtained from the Nebraska Transposon Mutant Library (NTML) [\[19](#page-12-7)] and transposon was transduced into our own JE2 background. The entire *gltT* locus with the transposon was amplified from the library isolate *SAUSA300\_2329* and the size of the PCR product was validated. This was performed using primers from outside of *gltT* to confirm transposon by amplicon size – 5′

<span id="page-1-0"></span>Table 1. List of *Staphylococcus aureus* strains used in this study. Plasmid pGltT was made as part of this study from the pOS1-P*lgT* vector using methods described in Potter *et al*. [\[18\]](#page-12-6). Fluorescent plasmids pCM29 [\[31\]](#page-12-8) and pHC48 [[20](#page-12-9)] and PAO1.GFP [\[48\]](#page-13-0) were obtained from Dr. Marvin Whiteley at the Georgia Institute of Technology



AAAATTAGCCTACCTATGCAAGTTGT 3′ and 5′ TTTTGCTTTGTCATATACGTTTTCC 3′. We also used the transposon specific primer to amplify DNA from within the transposon and the gene itself using the negative strand primer – 5' GCTT TTTCTAAATGTTTTTTAAGTAAATCAAGTAC 3′ as described by Fey *et al*. [[19\]](#page-12-7). The transposon within the *gltT* gene was transduced into our parental JE2 strain using phage φ11 [[20\]](#page-12-9) to generate strain JE2 *gltT*::Tn, as described below.

In brief, transduction was carried out by first preparing fresh φ11 lysate first with *S. aureus* strain RN4220. Collected lysate was then inoculated with NTML isolate S*AUSA300\_2329* and litres were measured at 3×10<sup>8</sup> plaque-forming units per millilitre. Transduction was then carried out with a multiplicity of infection of 0.1 according to methods in Krausz & Bose [\[21](#page-12-10)]. Transduced colonies were isolated on trypticase soy agar (TSA) (BD Difco) plates with 25 µg ml<sup>-1</sup> erythromycin and confirmed by PCR, identifying the presence of the complete transposon at the correct site on the chromosome, as described above.

Fluorescently labelled strains were generated by transforming multicopy plasmids obtained from Dr Marvin Whiteley's lab (Georgia Institute of Technology), pCM29 [[22](#page-12-11)] and pHC48 [[23](#page-12-12)] into both JE2 and JE2 *gltT*::Tn via electroporation [\[24](#page-12-13)]. This gave us the fluorescently labelled set JE2.GFP, JE2.DsRed, JE2 *gltT*::Tn.GFP and, JE2 *gltT*::Tn.DsRed ([Table 1\)](#page-1-0). Fluorecently labelled PAO1 [[https://pubmed.ncbi.nlm.nih.gov/9535661/\]](https://pubmed.ncbi.nlm.nih.gov/9535661/) was also obtained from Dr. Whiteley's lab; here we refer to this strain as PAO1.GFP.

### **Media**

Cocultures for evolution experiments and subsequent confirmatory coculture experiments were conducted on TSA. After each coculture period each species was isolated on their respective isolation agar, Pseudomonas isolation agar (PIA; BD Difco) and Staphylococcus isolation agar (SIA; TSA BD Difco with 7.5 % NaCl). For liquid cultures, bacteria were cultured in lysogeny broth (LB; Teknova) which was supplemented with erythromycin (25 µg ml−1) to select for transposon mutants and/or with chloramphenicol (10 μg ml<sup>-1</sup>) to maintain fluorescent plasmids. Chemically defined media with glucose (CDMG) was made according to Hussain *et al*. [[25\]](#page-12-14), with varying levels of aspartate (1.1 mM or 2.2 mM) and glutamate (1.0 mM or 2.0 mM), as needed (Supplementary Methods, available in the online version of this article). CDMG was always stored at room temperature, in the dark and used within 5 days. Depleted TSB medium, used for single-cell microscopy, was prepared by diluting an overnight culture of PAO1 1:100 into 10 ml TSB and growing the culture for either three or 16 h. Cultures were filter sterilized (0.2 µm filter, Sarstedt) to remove cells from the supernatant and referred to in this study as '3hr-depleted TSB' or '16hr-depleted TSB', respectively.

### **Experimental evolution**

To prepare for experimental evolution, four single colonies of JE2 were picked and grown individually in 3 ml of LB media in a test tube at 37 °C in a rolling drum incubator overnight. To prepare *S. aureus* for experimental evolution we first prepared *S. aureus* populations by spotting 10 µl of an overnight culture onto 0.45 µm filters (MF-Millipore Membrane Filter) on TSA and growing them at 37 °C for 24 h. This initial growth on plates was performed to create established *S. aureus* populations that had been 'primed' to grow on a solid surface. Each filter was collected, and adhering cells were resuspended in 1.5 ml of LB media by vortexing for 30 s. To prepare *P. aeruginosa* for coculturing, a single colony of PAO1 was incubated in 3 ml of LB media overnight at 37 °C in a rolling incubator. The optical density 600 nm (OD<sub>600</sub>) of the resuspended *S. aureus* as well as the overnight PAO1 culture was measured. Cultures were normalized to the same OD by diluting the PAO1 overnight culture in LB before inoculating a coculture at a ratio of 30:1 (*S. aureus:P. aeruginosa*). A 30:1 inoculum ratio was determined through preliminary experiments to exert optimal amount selective pressure on *S. aureus* without risking a population-level extinction (approximately a four-fold decrease in population size after coculture). To account for any adaptation to culture conditions, control populations of JE2 were passaged alongside the experimental populations under identical conditions, but never cocultured with PAO1.

For the rest of the evolution experiment, coculture periods began by spotting  $10 \mu l$  of (30:1) coculture mixtures or monocultures of *S. aureus* control populations onto 0.45 µm filters on TSA plates. All cultures were then incubated at 37 °C for 48 h. Cultures were then recovered for the next transfer by vortexing collected filters in 1.5 ml of LB media for 30 s to resuspend adhering cells. Resuspended cell mixtures were serially diluted and plated for CFUs on SIA and PIA media. Then 50 µl of resuspended coculture was also plated on SIA to be used to inoculate the next coculture. After 24 h of incubation at 37 °C, isolated *S. aureus* was then scraped off SIA plates with an inoculation loop and resuspended in LB media. This suspension was used to inoculate the next coculture period as well as to create a glycerol freezer stock of the recovered population of *S. aureus* for archiving ([Fig. 1a](#page-3-0)). The evolution experiment was carried out for eight consecutive 48 h coculture periods.

### **Whole genome sequencing**

Single colonies were isolated from evolved *S. aureus* populations and control populations and were used to inoculate overnight cultures and subsequent glycerol freezer stocks. Isolates were struck out on SIA plates and incubated overnight at 37 °C. Cells were collected off plates the next day and resuspended in 480 µl of EDTA. *S. aureus* cells were then lysed



<span id="page-3-0"></span>Fig. 1. Experimental evolution with *Staphylococcus aureus* USA300 JE2 generates populations that are tolerant to *Pseudomonas aeruginosa* PAO1 in coculture. (a) i) Coculture setup – *S. aureus* JE2 and *P. aeruginosa*, PAO1 were cocultured for 48h on solid TSA agar at an inoculation ratio of 30:1 (*S. aureus : P. aeruginosa*). A 0.45µm filter paper was used to contain and recover the entire culture. ii) After the coculture period, filters are resuspended in liquid media and serial dilutions of the resuspension are spot plated on selective agar. After 24h of growth, CFUs are counted for both species on their respective selective agar, SIA and PIA. iii) Then 50µl of each resuspended culture was also plated as a lawn onto a separate SIA plate. After overnight incubation, colonies recovered from these SIA lawns were used as the source of *S. aureus* for the next coculture period, which was then incubated with a fresh overnight culture of PAO1. OD<sub>600</sub> measurements were taken for both *S. aureus* and *P. aeruginosa* and the more dense was diluted to the same OD as the less dense suspension and the 30:1 ratio was mixed and inoculated onto filters. iv) Serial transfers are repeated for a total of eight consecutive coculture periods (T1–T8). Control populations are repeatedly transferred under the same conditions, but never exposed to *P. aeruginosa*. (b) Experimental evolution results: four populations (EE pop 1–4) were evolved in the presence of PAO1 for eight coculture periods; control population (passage alone) never exposed to *P. aeruginosa* also shown. The CFU counts from the first coculture period (initial) and eighth coculture period (final) are shown.

by adding 20 µl of 10 mg ml−1 lysozyme and 20 µl of 5 mg ml−1 lysostaphin (Sigma) to the resuspended cell mixture. This mixture was then incubated at 37 °C for 1 h before proceeding with the rest of the protocol outlined for the Promega Wizard genomic DNA purification kit [\[26](#page-12-15)]. Genomic DNA was sequenced using the Illumina NextSeq 2000 platform at the Microbial Genome Sequencing Center (Pittsburgh, PA). Whole genome sequences were evaluated for quality using the programme FASTQC [[27\]](#page-12-16) and adapter sequences were removed using Trimmomatic [[28\]](#page-12-17). Sequences were then screened for variants using snippy with JE2 NCBI NC\_007793.1 sequence as a reference [[29](#page-12-18)]. Sequences can be accessed via NCBI PRJNA1055168.

#### **Complementation of** *gltT*

The *gltT* gene was cloned using the multicopy pOS1 shuttle vector with the constitutive P*lgT* promoter [\[30, 31\]](#page-12-19). The *gltT* gene was amplified from wild-type JE2 using primers: 5′- AGAGCTCGAGATGGCTCTATTCAAGAG-3′ and 5′- AGAT GGATCCTTAAATTGATTTTAAATATTCTTGAC-3′ and cloned downstream of the P*lgT* promoter, in the pOS1-P*lgT* plasmid, as described in Potter *et al*. [\[18](#page-12-6)]. The resulting plasmid, pGltT, was confirmed by whole plasmid sequencing through Plasmidsaurus (Eugene, OR) (Fig. S1). pGltT was transformed via electroporation into JE2 *gltT*::Tn, as well as the evolved isolate, EV2. Vector controls (pOS1-P*lgT*) were also generated in all three strain backgrounds: JE2, EV2, and JE2 *gltT*::Tn. All plasmids were transformed using electroporation methods of Grosser & Richardson [\[24](#page-12-13)].

#### **Population screen for variation of** *gltT* **in** *S. aureus*

To determine the variability of *gltT,* we used a custom software, LIVID (<https://github.com/VishnuRaghuram94/LIVID>), which performs *in silico* PCR to extract nucleotide regions of interest from genome assemblies and compares the extracted sequence with a user-specified reference region to report mutations. LIVID was developed with similar methods as the tool AgrVATE discussed in Raghuram *et al*. [\[32](#page-12-20)]. For this analysis, we combined 380 assemblies from the Staphopia non-redundant diversity set [[33\]](#page-12-21) and 64 CF isolates [[16\]](#page-12-5) to create a dataset of 444 *S*. *aureus* genome assemblies. We then extracted and calculated the number of mutations in the genes *gltT, gltS, alsT, rpoD,* and *agrC,* using *S. aureus* strain JE2 (NCBI RefSeq accession GCF\_002993865.1) as a reference for LIVID. To account for different *agr* groups requiring a different reference sequence, we used the software tool AgrVATE [[32\]](#page-12-20) to calculate the number of mutations in *agrC*. Both LIVID and AgrVATE used snippy v4.6 for identifying mutations [\[29](#page-12-18)]. LIVID was run with the parameters -x 1000 (minimum product size) -y 2000 (maximum product size) -d 5 (maximum allowed primer mismatch bases). AgrVATE was run with default parameters, as described in Raghuram *et al*. [\[32](#page-12-20)]. Mutations labelled as 'synonymous' were single or multi-nucleotide substitutions that did not affect the amino acid sequence. Mutations labelled as 'AA-sequence altering' were single/multi-nucleotide substitutions in-frame insertions/deletions that cause local changes in the amino acid sequence. Putative 'loss of function' variants include frameshift mutations, start-codon variants and early stops caused by non-synonymous mutations.

#### **Testing for** *P. aeruginosa* **tolerance**

*S. aureus* tolerance to *P. aeruginosa* strain PAO1 was determined by coculturing *S. aureus* and PAO1 at high initial densities (>108CFUs) at a 1:1 ratio for 24 h and measuring recovered CFUs by serially diluting resuspended cultures and plating on SIA and PIA medias to select for *S. aureus* and *P. aeruginosa,* respectively [\[16](#page-12-5)]. Assays were carried out in at least five separate experiments with two biological replicates per strain.

#### **Murine acute pneumonia model**

The impact of *gltT* activity on *S. aureus* colonization was determined in a murine acute pneumonia model. All animal procedures were conducted in accordance with the guidelines of the Emory University Institutional Animal Care and Use Committee (IACUC), under approved protocol number PROTO201700441. Eight to 10week-old C57BL/6 female mice (Jackson Laboratories, Bar Harbour, ME) were anesthetized with a 0.2 ml mixture of ketamine (6.7 mg ml−1) and xylazine (1.3 mg ml−1) administered through intraperitoneal injection prior to infection. All mice were euthanized 24 h post-infection.

*S. aureus* strains JE2 and JE2 *gltT*::Tn were grown on SIA for 18 to 24 h at 37 °C and resuspended in phosphate buffered saline (PBS) to an OD<sub>600</sub> of 8, corresponding to ~2×10<sup>9</sup> CFU ml<sup>-1</sup>. Anesthetized mice were infected with 50 µl (~1×10<sup>8</sup> CFUs) of *S. aureus* through intranasal administration (25 µl per nostril). Following euthanasia, whole lungs and nasal washes were collected aseptically. The lungs were weighed and homogenized in 1 ml of PBS (bullet blender storm 5). Homogenized lungs and nasal wash were serially diluted and plated on SIA to determine CFUs. For the murine coinfections, JE2 and JE2 *gltT*::Tn were grown on SIA for 18 to 24 h at 37 °C and suspended in PBS to an OD<sub>600</sub> of 14, followed by a 1:2 dilution corresponding to ~4.8×10° CFU ml<sup>−1</sup> for each strain. Anesthetized mice were infected with 12.5 µl of culture of each *S. aureus* strain (~6×10<sup>7</sup> CFU) administered sequentially and single-strain control mice were infected with either 25 µl of JE2 or JE2  $gltT::Tn$  (~1×10<sup>8</sup>) CFU). Following euthanasia, whole lung and nasal wash were collected and processed following the procedures stated above. Serial dilutions were plated on both SIA and LA supplemented with erythromycin (25 µg ml<sup>-1</sup>) to determine CFUs for each strain in a coculture we subtracted the number of colonies on LA+erythromycin from the total number of colonies on SIA. Results were analysed using one-way analysis of variance (ANOVA) corrected with Šidák in GraphPad Prism nine.

### **Competitive fitness assay**

Strains JE2 and JE2 *gltT*::Tn fluorescently labelled with DsRed or GFP were grown individually and together in complete CDMG (1.1 mM aspartate and 1.0 mM glutamate) (+A/+G) or in CDMG with additional aspartate (2.2 mM aspartate) and no glutamate added (++A/0G). Cultures were inoculated at initial densities of OD<sub>600</sub> 0.01 in flasks with 25 ml of media and incubated at 37 °C with continuous shaking for 24 h. CFUs were determined at inoculation, early growth (4–8 h after inoculation) and endpoint (22–24 h after inoculation). Both versions of each strain – JE2.GFP and JE2.DsRed and JE2 *gltT*::Tn.GFP and JE2 *gltT*::Tn.DsRed – were tested in these conditions in replicate experiments.

### **Amino acid utilization**

Amplite Fluorimetric l-Aspartate (Aspartic Acid) Assay Kit, and Amplite Fluorimetric Glutamic Acid Assay Kit \*Red Fluorescence\* (AAT Bioquest) were used to measure the concentration of aspartate and glutamate, respectively. Cell-free media was collected by filtering resuspended cocultures that were grown for 24 h on TSA plates (as was done for testing for *P. aeruginosa*-tolerance) through 0.22 µm syringe filters. Remaining nutrients were measured in the resuspended media collected from *S. aureus* monocultures and cocultures, as well as PAO1 monocultures and controls. Controls were generated

by inoculating sterile filters with  $10 \mu l$  of LB or  $10 \mu l$  PBS and incubating for 24 h. Measurements were taken across three separate experiments, each with two replicates for each culture condition.

### **Single cell imaging**

Batch cultures were grown in TSB media supplemented with chloramphenicol ( $10 \,\mu g$  ml<sup>-1</sup>) to maintain fluorescent plasmids. Overnight cultures were diluted 1:100 into 3 ml fresh TSB media and grown to mid-exponential phase in a test tube at 37 °C in a shaking incubator (OD<sub>600</sub> between 0.5–0.8). Subsequently, cells were washed three times with PBS to remove antibiotics and diluted to an OD<sub>600</sub> of 0.1. Finally, a  $1 + 1 + 1$  coculture was prepared consisting of either JE2.DsRed + JE2 *gltT*::Tn.GFP + PAO1.GFP or JE2.GFP + JE2 *gltT*::Tn.DsRed + PAO1.GFP. Agarose media was prepared by adding 1.5 % agarose to either fresh or 3hr-depleted TSB or 16hr-depleted TSB.

A 1 ml droplet of agarose media was suspended between two coverslips and dried at room temperature for 30 min to create  $a \sim 3$  mm thick slab, which was then cut into 5×5 mm pads. Then 1 µl of the coculture was added to the pad and dried until the liquid was absorbed. Afterwards the pad was carefully inverted and placed in a glass-bottomed dish (WillCo Wells). Six pads were added to the same dish with the following media conditions: fresh TSB, 3hr-depleted TSB, and 16hr-depleted TSB. Each condition was inoculated with one of the two strain mixtures. A small piece of water-soaked tissue was added to preserve humidity and the dish was sealed with parafilm. The experiment was repeated four times using different biological replicates on two separate days. Four replicate experiments were conducted with each labelled version JE2.GFP+JE2 *gltT*::Tn. DsRed+PAO1.GFP or JE2.DsRed+JE2 *gltT*::Tn.GFP+PAO1.GFP with each *S. aureus* strain being tested twice. Imaging of the samples began 1 h after the agar pads were inoculated.

The pads were imaged using a Nikon Ti2 inverted microscope with perfect focus system, equipped with a Hamamatsu ORCA-Flash4.0 V3 Digital CMOS camera, a Nikon NA1.42 60X Plan Apochromat phase contrast oil objective, a SPECTRA-X LED fluorescent light source, and Chroma filter sets. Images were taken every 3 min in the phase, GFP, and DsRed channels. Cells were kept at 37 °C while imaging using a climate-controlled incubator (Oko-lab).

#### **Image analysis**

To analyse colony growth, we segmented and tracked colonies using a custom-build pipeline (code available at: [https://](https://github.com/simonvanvliet/PA-SA_Agarpads) [github.com/simonvanvliet/PA-SA\\_Agarpads\)](https://github.com/simonvanvliet/PA-SA_Agarpads). The time-lapse movies were manually trimmed to remove later time points where cells overlapped in 3D or where excessive cell movement of *P. aeruginosa* was observed. Subsequently, images were registered using the phase\_cross\_correlation method of scikit-image [\[34](#page-13-1)]. Segmentation of colony outlines was done using the Ilastik supervised pixel classification workflow [[35\]](#page-13-2). Pixels in the multi-channel image (phase, GFP, DsRed) were classified in four classes (GFP-labelled *S. aureus*, DsRed-labelled *S. aureus*, *P. aeruginosa*, and background). The classification probabilities were post-processed using custom written python code to extract individual masks for each colony. Briefly, the probabilities were smoothed with a gaussian kernel and thresholded using a fixed threshold value of 0.5. The masks were then post-processed using a binary closing operation to fill-in gaps between neighbouring cells. Finally, small objects were removed, and holes closed.

Colonies were tracked using a custom written tracking algorithm that matched colonies across subsequent frames based on the minimal center-to-center distance. Tracks were stopped when colonies merged. An automated filtering procedure was used to trim tracks whenever an unexpectedly large change in colony area was observed (indicative of missed colony merger and/or segmentation error).

Colony growth rate, *r*, was calculated as:  $r = \frac{1}{\Delta t} \log \frac{A(T)}{A(0)}$  $\frac{A(1)}{A(0)}$ , where  $A(0)$  and  $A(T)$  are the area (in pixels squared) of the colony at the start of the movie and after *T*=1h, with ∆*t*=3min as the imaging interval. To quantify the spatial arrangement, we calculated the minimal distance reached between the edge of the focal *S. aureus* colony to the closest pixel occupied by *P. aeruginosa*. Colonies within 300 pixels of the image frame were excluded from the analysis, as we could not accurately quantify their spatial arrangement.

## **RESULTS**

#### **g***ltT* **truncation in** *S. aureus* **is an adaptation to** *P. aeruginosa* **tolerance**

To monitor *S. aureus'* ability to adapt to the presence of *P. aeruginosa*, we evolved four replicate populations from four individual colonies of *S. aureus* strain JE2 under repeated exposure to *P. aeruginosa* strain PAO1. This was done by coculturing evolving *S. aureus* populations with PAO1 for 48h on filters on TSA plates. Using filters allowed the entire coculture to be recovered after incubation. Coculture filters were then resuspended in LB and the number of *S. aureus* surviving PAO1 treatment after each coculture period was determined by plating onto selective agar and used for the next coculture experiment with fresh PAO1 ([Fig. 1a\)](#page-3-0). We chose to conduct this experiment with reference strains of *P. aeruginosa* and *S. aureus* (PAO1 and JE2, respectively)

for which ordered transposon-mutant libraries are available so that we could easily confirm our results and test for the fitness effects of any mutation that arose in non-essential genes.

Serial transfer experimental evolution yielded populations of *S. aureus* with improved survival in the presence of *P. aeruginosa* strain PAO1. At the completion of eight repeated 48h coculture periods, two out of four experimental *S. aureus* populations had increased their relative survival three-fold compared to the JE2 ancestral strain. Evolved populations, EE pop 1 and EE pop 3, both increased in the number of recovered CFUs by more than three orders of magnitude, with about 10<sup>5</sup> CFUs being initially recovered to about 10° CFUs recovered after eight serial transfers [\(Fig. 1b\)](#page-3-0). Similar results were observed in replicate evolution experiments.

Two single-colony-isolates each from an evolved *Pseudomonas-*tolerant population (EE pop 1), an evolved *Pseudomonas-*sensitive population (EE pop 4), and control population isolates that were transferred in parallel but never cultured with PAO1 were obtained. The phenotype was confirmed for these single colony isolates by screening for their tolerance to PAO1 in a 1:1 24h culture on solid TSA agar (Fig. S2A). These strains were subjected to whole genome sequencing which revealed that in the evolved-tolerant isolates, EV2 and EV3, there was only one gene that contained mutations that did not appear in the sequences of the evolved but still sensitive isolate, or control population isolates. We observed that each of the evolved-tolerant isolates, EV2 and EV3, had an independent putative loss of function mutation in the gene encoding for the *S. aureus* amino acid transporter, *gltT*. In isolate EV3, a single nucleotide base substitution G → A introduced an early stop; in isolate EV2, a four-base-pair deletion resulted in a frameshift mutation [\(Fig. 2a\)](#page-6-0). Both mutations occurred between 800–1200bp downstream of the start codon



<span id="page-6-0"></span>

and were predicted to truncate the protein by disrupting the 3′ portion of the coding region. All sequences can be found at NCBI PRJNA1055168. Both isolates displayed a *P. aeruginosa-*tolerant phenotype compared to their common ancestor, JE2 (Fig. S2B). GltT has been previously described as being the sole aspartate transporter in *S. aureus* that also interacts with glutamate [[18, 36, 37\]](#page-12-6). EV2 was selected to be used in further experiments as the comparative evolved isolate.

To confirm the linkage between *gltT* disruption and *P. aeruginosa-*tolerant phenotype, we obtained the *gltT* mariner transposon knockout mutant, *SAUSA300\_2329* from the Nebraska Transposon Mutant Library (NTML) [\[19](#page-12-7)]. We transduced the mutation to the ancestral JE2 background, and confirmed the genotype of this strain, which we now refer to as JE2 *gltT*::Tn, had improved CFU recovery after coculture with PAO1 compared to its parent ([Fig. 2b\)](#page-6-0). These results confirm that the *gltT* disruption was responsible for the enhanced fitness of *S. aureus* in coculture with PAO1. When the *gltT* mutants were complemented *in trans* with the wild-type *gltT* gene on the plasmid pGltT, the PAO1 sensitivity phenotype was restored to both the JE2 *gltT*::Tn, and the evolved isolate EV2 [\(Fig. 2b\)](#page-6-0).

## **JE2** *gltT***::Tn outcompetes wild-type** *S. aureus* **JE2 in CDMG without glutamate**

Growing strains individually in rich LB media (Fig. S3) yielded no significant growth differences associated with *gltT* disruption. However, we hypothesized that *gltT* mutants may be able to outcompete wild-type *S. aureus* under certain conditions. To test this, we conducted competition experiments with mutant and wild-type strains fluorescently labelled with either GFP or DsRed multicopy plasmids – pCM29 and pCH48, respectively. Labelled strains were inoculated in complete CDMG that had final concentrations of 1.1 mM aspartate and 1.0 mM glutamate (+A/+G) or in CDMG with double the amount of aspartate (2.2 mM aspartate) and no glutamate added  $(+A/0G)$ . The CFU counts showed that JE2 and JE2  $gltT::Tn$  were equally fit when grown in complete CDMG, with each strain making up about half of the total culture density. All cultures grew to similar final densities, >10<sup>8</sup> CFUs ml<sup>−1</sup>. However, when grown together with excess aspartate and no glutamate (++A/0G), JE2 *gltT*::Tn outcompeted wild-type JE2; JE2 only made up about 5 % of all CFUs recovered from this growth condition ([Fig. 3\)](#page-7-0). When grown in isolation (not in coculture) both wild-type and *gltT* mutant strains maintained similar growth rates and yields under all conditions tested (Table S1).

### **Growth rate differences, as measured by single cell microscopy, are not responsible for the** *P. aeruginosa***tolerant phenotype**

To test whether growth rate differences in the presence of PAO1 could be observed microscopically, we conducted single cell image analysis on cocultures with equal starting ratios of JE2, JE2 *gltT*::Tn and PAO1 and GFP and DsRed fluorescentlylabelled strains. Despite the evidence we observed from the CFU data, we did not observe measurable growth differences between the two strains when grown in the presence of PAO1. We also hypothesized that growth rate differences may only

<span id="page-7-0"></span>

Fig. 3. JE2 gltT::Tn outcompetes wild-type JE2 in CDMG when glutamate is limiting and aspartate is in excess. Fluorescently labelled strains: JE2. GFP, JE2.DsRed, JE2 *gltT*::Tn.GFP, and JE2 *gltT*::Tn.DsRed were used to test for competitive fitness in CDMG conditions. One GFP labelled strain and one DsRed labelled strain were cultured for 24h in CDMG media alone and in coculture. Incubated cultures were then serially diluted and incubated overnight at 37°C before CFUs were counted and number of red and green colonies recorded. Each combination strains were tested at least once across three biological replicates. In the complete CDMG condition with aspartate and glutamate in normal amounts (+A/+G) JE2 and JE2 *gltT*::Tn each made up about half of the measured CFUs in coculture. JE2 *gltT*::Tn made up the majority of CFUs recovered after 24h in CDMG when aspartate (A) was in excess (++), and glutamate (G) was limited (0G) (++A/0G) Chi-square *p*-value<0.0001.



<span id="page-8-0"></span>Fig. 4. Growth rates of wild-type JE2 and JE2 *gltT*::Tn plotted against distance to nearest PAO1 cell. Fluorescently labelled strains: JE2.GFP and JE2 *gltT*::Tn.DsRed or JE2.DsRed and JE2 *gltT*::Tn.GFP were cultured with PAO1 on agar pads made from rich Trypticase Soy Broth (TSB) and 3hr-depleted TSB (TSB3h) and 16hr-depleted TSB (TSB16h). All depleted media was made by culturing PAO1 monocultures for the designated time and then collecting cell-free media. Growth rates were measured using single cell microscopy image analysis. Wild-type JE2 growth advantage over mutant JE2 *gltT*::Tn slightly increases with distance to PAO1 in 3hr-depleted TSB. However, strains grow generally at the same rate in all other conditions. Data was collected over four replicates for each of the two strain combinations. We did not observe consistent differences between the different DsRed or GFP strain combinations and their data was thus pooled. PAO1.GFP also carried a GFP label and was easily distinguished based on cell shape. The two-way ANOVA revealed significant effects of media (F(2, 18) = 11800.29, *P*<0.001) and genotype (F(1, 18) = 4.37, *P*=0.036), as well as a significant interaction between media and genotype (F(2, 18) = 17.55, *P*<0.001) on growth. Post-hoc Tukey's HSD test indicated significant differences between different media conditions (P<0.05), suggesting that the growth varied significantly depending on the media used. Additionally, significant differences were observed between genotypes in the 3hr-depleted TSB (*P*<0.05).

be apparent in depleted media conditions. However, even in 16hr-depleted TSB (collected from a 16 h culture of PAO1), JE2 *gltT*::Tn did not have an observable difference in growth rate compared to wild-type JE2 [\(Fig. 4](#page-8-0)). Moreover, we did not find a dependence of *S. aureus* growth rates for either wild-type JE2 or JE2 *gltT*::Tn based on their proximity to PAO1 colonies. In fact, the only growth difference observed was a slight advantage for wild-type JE2 in 3hr-depleted TSB. Both strains had very low growth rates in 16hr-depleted TSB.

#### **g***ltT* **disruption alters amino acid uptake in** *S. aureus* **strains**

We measured concentrations of aspartate and glutamate in cell-free resuspended media that was collected from 24 h TSA cultures of the following *S. aureus* strains cultured alone or in the presence of PAO1: JE2, JE2 *gltT*::Tn, EV2 and complemented strains JE2 *gltT*::Tn(pGltT) and EV2(pGltT). These data revealed that aspartate was in higher abundance than glutamate on filters incubated on TSA. Aspartate concentration remained highest in all culture conditions where PAO1 was absent ([Fig. 5](#page-9-0)). In the case of glutamate, there was very little of the amino acid remaining in any culture condition with wild-type or *gltT* complemented *S. aureus* strains (<10 µM). Both amino acids were present at higher concentrations in the resuspended media of 24 h, *S. aureus* monocultures compared that of cocultures or PAO1 monocultures [\(Fig. 5](#page-9-0)).

#### **g***ltT* **disruption does not impact** *S. aureus* **mouse respiratory colonization**

To gain an understanding of the impact of *gltT* disruption in a host environment, we carried out experiments using an acute murine pneumonia model system where mice were infected with JE2 *gltT*::Tn*,* wild-type JE2, or both strains in a coinfection. There were similar population sizes of the ancestral JE2 strain and JE2 *gltT*::Tn recovered from both the nasal wash and lung tissue for both single strain cultures and cocultures of the two strains [\(Fig. 6](#page-9-1)). Therefore, we concluded that *gltT* disruption did not greatly impact *S. aureus'* ability to colonize host respiratory tissues.

#### **g***ltT* **disruption was rare in diverse** *S. aureus* **genomes**

To determine the prevalence of *gltT* mutation in *S. aureus*, we performed *in silico* PCR analysis of a set of diverse *S. aureus* genomes. Using this approach, we did not observe a significant enrichment of mutations in *gltT* when compared to other amino acid transporters in our dataset of 444 genomes. We observed 115 occurrences of non-synonymous mutations in *gltT*, with 26 distinct mutations, 25 of which were found in <10 strains. One mutation – a glutamate → aspartate change at position 891, was found in 71 strains. We compared this mutation rate to that of *gltS,* the *S. aureus* glutamate transporter, and found *gltT* to have a lower occurrence of mutations compared to this similarly functioning protein. Overall, these results suggest that *gltT* disruption is rare in *S. aureus*, even compared to other core genes encoding amino acid transporters (Table S2).



<span id="page-9-0"></span>Fig. 5. *gltT* disruption reduces *S. aureus* glutamate uptake; aspartate and glutamate are greatly reduced when PAO1 is present. Remaining aspartate and glutamate levels after 24h of culturing on 0.45µM filters on TSA plates, were measured using Amplite Fluorimetric kits. Cocultures with PAO1 (Cocul), *S. aureus* monocultures (Sa alone), and *P. aeruginosa* monocultures (Pa alone), were tested. Control conditions were tested by inoculating filters with 10 µl of LB media or 10 µl of PBS.

Findings from the evolution experiment and *gltT* mutant phenotyping tests indicated that *gltT* could be disrupted without severe impacts on strain fitness. We, therefore, sought to estimate the variability of *gltT* across diverse *S. aureus* lineages, including CF-associated isolates. Previous work had shown that *gltT* is a core gene and so we were able to look at *gltT* variability by screening our dataset of *S. aureus* genomes representing 380 MLST sequence types [\[33](#page-12-21)]. We did not find mutations identical to the ones we identified during our experimental evolution in any genomes, including CF associated isolates. Furthermore, we identified only one mutation that caused an early stop, at position 1255, truncating the protein by eight amino acids. This was the only putative non-functional mutant we observed in *gltT* and it was present in only one sample, which was not isolated from a CF-associated infection or known coinfection with *P. aeruginosa*.



<span id="page-9-1"></span>



<span id="page-10-0"></span>Fig. 7. *S. aureus* adapts to the limitation of glutamate in the presence of *P. aeruginosa* by disrupting the aspartate transporter, *gltT*. Evidence gathered in our study points to this proposed model of *Pseudomonas*-tolerance by evolved *S. aureus* where wild-type JE2 (left) is effectively outcompeted by *gltT* mutant JE2 *gltT*::Tn (right) in CDMG with no glutamate and maintains large populations in the presence of PAO1. We postulate that disrupting *gltT* enables *Pseudomonas*-tolerance in strains with a disrupted *gltT* locus because they do not incur the costs of importing extracellular aspartate in a glutamate limited environment when *Pseudomonas* consumes the majority of available amino acids.

# **DISCUSSION**

#### **A newly recognized role for the** *gltT* **gene influencing** *S. aureus* **and** *P. aeruginosa* **interactions**

Interactions between *S. aureus* and *P. aeruginosa* have proven to be complex, and dependent on environment and strain background [[12, 16, 38–41\]](#page-12-4). Studies have implicated factors such as the *P. aeruginosa* mucoid phenotype, *Pseudomonas* excreted compounds or toxins, and *S. aureus* metabolic pathways such as the production of acetoin, as important factors in the interspecific interactions between *S. aureus* and *P. aeruginosa* [[7, 8, 16, 38, 42, 43](#page-12-2)]. Surprisingly, despite the wealth of research on interaction of these species, in our experimental system, we observed the mutation of a highly conserved gene, *gltT,* which had not previously been linked to *S. aureus-P. aeruginosa* interactions. Our findings suggest that *S. aureus* JE2 and *P. aeruginosa* PAO1 directly compete over limiting glutamate, particularly when grown at high densities on TSA plates. Our evolved isolates appear to have gained a phenotypic advantage over their JE2 ancestor by disrupting the *gltT* locus – limiting import of aspartate and glutamate and likely relying on alternative metabolic pathways. Under the conditions of the evolution experiment we designed here, there appears to be significant selective pressure for *S. aureus* to optimize its amino acid metabolism by reducing aspartate uptake potentially in response to PAO1-induced glutamate limitation ([Fig. 7](#page-10-0)). Previous work has demonstrated that the *S. aureus gltT* gene is important in osteomyelitis where glutamate competitively inhibits aspartate transport through *gltT* [\[18](#page-12-6)]. While the osteomyelitis study above presents the inverse of the nutrient landscape that *S. aureus* is adapting to as compared to our experiment – a challenge of excess glutamate rather than it being a limiting nutrient – it also demonstrates the importance of exogenous amino acids in *S. aureus* competitive fitness and the importance of altering metabolic pathways as an adaptive strategy in changing environments. In the CF lung environment, previous work has indicated that glutamate may be freely available while aspartate is potentially limited [[44\]](#page-13-3). Other studies have found that levels of glutamate and aspartate are both elevated in the CF lung and sinuses compared to non-CF lung and sinus environments [[45\]](#page-13-4). It is difficult to know what micro-climates bacterial populations may find themselves in an environment with extensive surface area like the lung. It is also not known and how the presence of different species may alter the availability of nutrients for resident or invading populations. Our findings suggest that we still do not understand enough about the interaction between *S. aureus* and *P. aeruginosa* to predict the influential genes and advantageous factors in any given combination of strains and environmental conditions.

We acknowledge some limitations of our experimental evolution approach. For instance, while fresh PAO1 was introduced to each coculture period, we found that a minority population of *P. aeruginosa* were able to survive on SIA agar even though they did not form colonies. Thus we suspect that some *P. aeruginosa* cells were transferred between coculture periods and may have coevolved with the JE2 populations. However, fresh PAO1 was introduced at each coculture period, and the evolved *P. aeruginosa-*tolerant phenotypes of *S. aureus* were maintained after populations were fully isolated from any retained PAO1. Therefore, the effect of carryover *P. aeruginosa* was expected to be very small compared to the larger population of fresh introduced ancestral PAO1. Additionally, the intention with our evolution experiment design was not to exactly replicate phenomena that occur between *S. aureus* and *P. aeruginosa* in coinfections, rather we sought to observe the effect that *P. aeruginosa* has on *S. aureus* evolution in a neutral environment. The nutrient landscape of TSA is likely quite different compared to host environments as there are no selective forces from a host itself or an immune system present. Furthermore,

our use of filters on agar lacks a structural environment that could allow for spatial segregation of the two species. Culturing recovery populations for 24 h on TSA agar before transferring to the next coculture period also presumably selected against slow-growing phenotypes like small colony variants, which have been observed to be associated with *S. aureus* co-occurring with *P. aeruginosa* in coinfections [[46\]](#page-13-5). Note that we did not observe small colony variants in any of our evolved populations or when we monitored *S. aureus* at the single-cell level. However, in the neutral environment we facilitated on TSA plates or on agar pads in our single-cell imaging experiment, we were able to observe the effects of the strong selective pressures presented by co-occurring *P. aeruginosa* on evolving *S. aureus* populations and were able to isolate novel genetic determinants thereof.

### **A model for the role of aspartate and glutamate in** *P. aeruginosa* **tolerance**

Previous analysis of *S. aureus* metabolism has shown that glutamate derivatives are required for *S. aureus* to metabolize aspartate into oxaloacetate, a secondary metabolite required in the citric acid cycle [\[47](#page-13-6)]. Therefore, the absence of extracellular glutamate may lead to reduced activity of the TCA cycle ([Fig. 7](#page-10-0)). This could explain why all tested *S. aureus* strains showed a reduced growth-rate when glutamate was not present in CDMG compared to CDMG with  $1.0 \mu$ M of initial glutamate (Supplementary Results, Table S1). As for the role of *gltT* disruption in *S. aureus* metabolism – we did not observe significant growth rate differences between wild-type JE2 *S. aureus* and JE2 *gltT*::Tn in our CDMG monoculture assays or by single-cell microscopy. We did however, observe interesting results when looking at remaining amino acid concentrations after culturing *S. aureus* strains and PAO1 together and alone. We saw that PAO1 was more efficient than all *S. aureus* strains at consuming both glutamate and aspartate, leaving very little of either amino acid behind whenever present. Our data suggest that this may be the primary condition that selects for the disruption of *S. aureus gltT* during these coculture experimental evolution studies. The levels of remaining aspartate were higher in *S. aureus* cultures of the *gltT* mutant, which was expected due to the disruption of the main aspartate transporter. However, we also observed higher levels of glutamate remaining for *gltT* mutants, and restored wild-type phenotypes in complemented strains, suggesting that a functional *gltT* locus was essential to utilizing most of the available glutamate ([Fig. 5](#page-9-0)). Interestingly, complemented strains showed similar aspartate utilization as their parent strains suggesting that *gltT* activity did not largely impact how much aspartate a strain consumed, however in general, *S. aureus* monocultures did not consume very much available aspartate. It was previously known that glutamate could be transported through *gltT* [[18\]](#page-12-6)*,* however, *gltS* was thought to be largely responsible for transporting the majority of glutamate [[36\]](#page-13-7). Our findings here suggest that *gltT* plays a larger role in glutamate acquisition than previously thought.

These data suggest that despite its important role in amino acid metabolism, there were few apparent fitness trade-offs associated with disrupting *gltT* when strains are grown in isolation [[37\]](#page-13-8). However, the finding that *gltT* mutations are extremely rare in non-laboratory-adapted strains reinforces the key metabolic role of this core gene. We postulate that continuing to import aspartate in the wild-type strain in the absence of glutamate may lead to a buildup of aspartate intracellularly and a corresponding reduced competitive fitness. This hypothesis is supported by our finding that along with its increased *P. aeruginosa*-tolerance, JE2 *gltT*::Tn was able to outcompete wild-type JE2 in the CDMG condition where additional aspartate was added and no glutamate was added  $(++A/OG)$  [\(Fig. 3](#page-7-0)).

Further experimentation is needed to better understand how amino acid metabolism facilitates *S. aureus-P. aeruginosa* interactions; however, we conclude here that in this evolution experiment, *S. aureus* is primarily adapting to the limitation of glutamate in its environment by disrupting its aspartate transporter and relying on alternative metabolic pathways to carry out the TCA cycle. In short, the major source of negative selective pressure that *S. aureus* experienced when grown in the presence of *P. aeruginosa* was competition over exogenous amino acids.

### *In vitro* **experimental evolution is a useful tool for studying pathogens**

Experimental or directed evolution experiments carried out in laboratory conditions can be a powerful way to reduce complex adaptive phenotypes in important pathogens like *S. aureus* and *P. aeruginosa* to single genetic determinants. Our findings here lay important groundwork for understanding the development of coinfections by highlighting the importance of nutrient availability in the facilitation of *S. aureus-P. aeruginosa* coexistence. Because *gltT* is so highly conserved in natural populations, the link between *gltT* and *P. aeruginosa* tolerance likely could not have been identified by studying clinical isolates alone. Our *in vitro* experiments suggest that while rare, *gltT* mutants can colonize lung tissue just as well as wild-type strains and would be more likely to coexist with *Pseudomonas* in a coinfection due to their increased tolerance of co-occurring *P. aeruginosa*. Therefore, this genotype could be important to screen for when treating coinfections and is certainly important to consider in the development of new therapies that may alter the availability of nutrients in the infection environment.

Funding information

Research reported in this publication was supported in part by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number T32AI138952. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported in this publication was supported by Emory University and the Infectious Disease Across Scales

Training Programm (IDASTP). The content is solely the responsibility of the authors and does not necessarily represent the official views of Emory University or IDASTP. This work was supported in part with grants for the National Institutes of Health (R21 AI148847) and the US Cystic Fibrosis Foundation (GOLDBE19I0) to J.B.G. G.B. and S.V.V. were supported by an Ambizione grant from the Swiss National Science Foundation (grant no. PZ00P3\_202186) and by the University of Basel.

#### Acknowledgements

We would like to thank Rachel Done for her assistance with cloning and strain construction.

#### Conflicts of interest

The authors declare no potential conflicts of interest.

#### Refrences

- <span id="page-12-0"></span>1. Brown SP, Cornforth DM, Mideo N. Evolution of virulence in opportunistic pathogens: generalism, plasticity, and control. *Trends Microbiol* 2012;20:336–342.
- 2. Brown SP, Le Chat L, Taddei F. Evolution of virulence: triggering host inflammation allows invading pathogens to exclude competitors. *Ecol Lett* 2008;11:44–51.
- 3. Dalton T, Dowd SE, Wolcott RD, Sun Y, Watters C, *et al*. An in vivo polymicrobial biofilm wound infection model to study interspecies interactions. *PLoS One* 2011;6:e27317.
- 4. Stacy A, Fleming D, Lamont RJ, Rumbaugh KP, Whiteley M. A commensal bacterium promotes virulence of an opportunistic pathogen via cross-respiration. *mBio* 2016;7:e00782-16.
- 5. Wadsworth CB, Arnold BJ, Sater MRA, Grad YH. Azithromycin resistance through interspecific acquisition of an epistasisdependent efflux pump component and transcriptional regulator in *Neisseria gonorrhoeae*. *mBio* 2018;9:10..
- <span id="page-12-1"></span>6. Hamelin FM, Allen LJS, Bokil VA, Gross LJ, Hilker FM, *et al*. Coinfections by noninteracting pathogens are not independent and require new tests of interaction. *PLoS Biol* 2019;17:e3000551.
- <span id="page-12-2"></span>7. Barraza JP, Whiteley M. A *Pseudomonas aeruginosa* antimicrobial affects the biogeography but not fitness of *Staphylococcus aureus* during coculture. *mBio* 2021;12:e00047-21.
- 8. Camus L, Briaud P, Bastien S, Elsen S, Doléans-Jordheim A, *et al*. Trophic cooperation promotes bacterial survival of *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *ISME J* 2020;14:3093–3105.
- <span id="page-12-3"></span>9. Filkins LM, Graber JA, Olson DG, Dolben EL, Lynd LR, *et al*. Coculture of *Staphylococcus aureus* with *Pseudomonas aeruginosa* drives *S. aureus* towards fermentative metabolism and reduced viability in a cystic fibrosis model. *J Bacteriol* 2015;197:2252–2264.
- 10. Jenul C, Keim KC, Jens JN, Zeiler MJ, Schilcher K, *et al*. Pyochelin biotransformation by *Staphylococcus aureus* shapes bacterial competition with *Pseudomonas aeruginosa* in polymicrobial infections. *Cell Rep* 2023;42:112540.
- 11. Limoli DH, Whitfield GB, Kitao T, Ivey ML, Davis MR, *et al*. *Pseudomonas aeruginosa* alginate overproduction promotes coexistence with *Staphylococcus aureus* in a model of cystic fibrosis respiratory infection. *mBio* 2017;8:e00186–17.
- <span id="page-12-4"></span>12. Niggli S, Schwyter L, Poveda L, Grossmann J, Kümmerli R. Rapid and strain-specific resistance evolution of *Staphylococcus aureus* against inhibitory molecules secreted by *Pseudomonas aeruginosa mBio* 2023;14:e0315322.
- 13. Limoli DH, Yang J, Khansaheb MK, Helfman B, Peng L, *et al*. *Staphylococcus aureus* and *Pseudomonas aeruginosa* co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes. *Eur J Clin Microbiol Infect Dis* 2016;35:947–953.
- 14. Nguyen AT, O'Neill MJ, Watts AM, Robson CL, Lamont IL, *et al*. Adaptation of iron homeostasis pathways by a *Pseudomonas aeruginosa* pyoverdine mutant in the cystic fibrosis lung. *J Bacteriol* 2014;196:2265–2276.
- 15. Orazi G, O'Toole GA. *Pseudomonas aeruginosa* alters *Staphylococcus aureus* sensitivity to vancomycin in a biofilm model of cystic fibrosis infection. *mBio* 2017;8:e00873-17.
- <span id="page-12-5"></span>16. Bernardy EE, Petit RA, Raghuram V, Alexander AM, Read TD, *et al*. Genotypic and phenotypic diversity of *Staphylococcus aureus* isolates from cystic fibrosis patient lung infections and their interactions with *Pseudomonas aeruginosa*. *mBio* 2020;11:e00735-20.
- 17. Wieneke MK, Dach F, Neumann C, Görlich D, Kaese L, *et al*. Association of diverse *Staphylococcus aureus* populations with *Pseudomonas aeruginosa* coinfection and inflammation in cystic fibrosis airway infection. *mSphere* 2021;6:e0035821.
- <span id="page-12-6"></span>18. Potter AD, Butrico CE, Ford CA, Curry JM, Trenary IA, *et al*. Host nutrient milieu drives an essential role for aspartate biosynthesis during invasive *Staphylococcus aureus* infection. *Proc Natl Acad Sci U S A* 2020;117:12394–12401.
- <span id="page-12-7"></span>19. Fey PD, Endres JL, Yajjala VK, Widhelm TJ, Boissy RJ, *et al*. A genetic resource for rapid and comprehensive phenotype screening of nonessential *Staphylococcus aureus* genes. *mBio* 2013;4:e00537–12.
- <span id="page-12-9"></span>20. Iandolo JJ, Worrell V, Groicher KH, Qian Y, Tian R, *et al*. Comparative analysis of the genomes of the temperate bacteriophages phi 11, phi 12 and phi 13 of *Staphylococcus aureus* 8325. *Gene* 2002;289:109–118.
- <span id="page-12-10"></span>21. Krausz KL, Bose JL. Bacteriophage transduction in *Staphylococcus aureus*: broth-based method. In: Bose JL (eds). *The Genetic Manipulation of Staphylococci: Methods and Protocols*. New York: Springer; 2016. pp. 63–68.
- <span id="page-12-11"></span>22. Pang YY, Schwartz J, Thoendel M, Ackermann LW, Horswill AR, *et al*. agr-Dependent interactions of *Staphylococcus aureus* USA300 with human polymorphonuclear neutrophils. *J Innate Immun* 2010;2:546–559.
- <span id="page-12-12"></span>23. Ibberson CB, Parlet CP, Kwiecinski J, Crosby HA, Meyerholz DK, *et al*. Hyaluronan modulation impacts *Staphylococcus aureus* biofilm infection. *Infect Immun* 2016;84:1917–1929.
- <span id="page-12-13"></span>24. Grosser MR, Richardson AR. Method for preparation and electroporation of *S. aureus* and *S. epidermidis*. In: Bose JL (eds). *The Genetic Manipulation of Staphylococci: Methods and Protocols*. New York: Springer; 2016. pp. 51–57.
- <span id="page-12-14"></span>25. Hussain M, Hastings JGM, White PJ. A chemically defined medium for slime production by coagulase-negative staphylococci. *J Med Microbiol* 1991;34:143–147.
- <span id="page-12-15"></span>26. Silberstein E, Serna C, Fragoso SP, Nagarkatti R, Debrabant A. A novel nanoluciferase-based system to monitor *Trypanosoma cruzi* infection in mice by bioluminescence imaging. *PLoS One* 2018;13:e0195879.
- <span id="page-12-16"></span>27. Wingett SW, Andrews S. FastQ Screen: a tool for multi-genome mapping and quality control. *F1000Res* 2018;7:1338.
- <span id="page-12-17"></span>28. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 2014;30:2114–2120.
- <span id="page-12-18"></span>29. Seeman T. snippy: fast bacterial variant calling from NGS reads; 2015. <https://github.com/tseemann/snippy>
- <span id="page-12-19"></span>30. Bubeck Wardenburg J, Williams WA, Missiakas D. Host defenses against *Staphylococcus aureus* infection require recognition of bacterial lipoproteins. *Proc Natl Acad Sci U S A* 2006;103:13831–13836.
- <span id="page-12-8"></span>31. Schneewind O, Model P, Fischetti VA. Sorting of protein A to the staphylococcal cell wall. *Cell* 1992;70:267–281.
- <span id="page-12-20"></span>32. Raghuram V, Alexander AM, Loo HQ, Petit RA 3rd, Goldberg JB, *et al*. Species-wide phylogenomics of the *Staphylococcus aureus Agr* operon revealed convergent evolution of frameshift mutations. *Microbiol Spectr* 2022;10:e0133421.
- <span id="page-12-21"></span>33. Petit RA 3rd, Read TD. *Staphylococcus aureus* viewed from the perspective of 40,000+ genomes. *PeerJ* 2018;6:e5261.
- <span id="page-13-1"></span>34. van der Walt S, Schönberger JL, Nunez-Iglesias J, Boulogne F, Warner JD, *et al*. scikit-image: image processing in Python. *PeerJ* 2014;2:e453.
- <span id="page-13-2"></span>35. Berg S, Kutra D, Kroeger T, Straehle CN, Kausler BX, *et al*. ilastik: interactive machine learning for (bio)image analysis. *Nat Methods* 2019;16:1226–1232.
- <span id="page-13-7"></span>36. Zeden MS, Kviatkovski I, Schuster CF, Thomas VC, Fey PD, *et al*. Identification of the main glutamine and glutamate transporters in *Staphylococcus aureus* and their impact on c-di-AMP production. *Mol Microbiol* 2020;113:1085–1100.
- <span id="page-13-8"></span>37. Zhao H, Roistacher DM, Helmann JD. Aspartate deficiency limits peptidoglycan synthesis and sensitizes cells to antibiotics targeting cell wall synthesis in *Bacillus subtilis*. *Mol Microbiol* 2018;109:826–844.
- 38. Bernardy EE, Raghuram V, Goldberg JB. *Staphylococcus aureus* and *Pseudomonas aeruginosa* isolates from the same cystic fibrosis respiratory sample coexist in coculture. *Microbiol Spectr* 2022;10:e0097622.
- 39. Briaud P, Camus L, Bastien S, Doléans-Jordheim A, Vandenesch F, *et al*. Coexistence with *Pseudomonas aeruginosa* alters *Staphylococcus aureus* transcriptome, antibiotic resistance and internalization into epithelial cells. *Sci Rep* 2019;9:16564.
- 40. Limoli DH, Warren EA, Yarrington KD, Donegan NP, Cheung AL, *et al*. Interspecies interactions induce exploratory motility in *Pseudomonas aeruginosa*. *Elife* 2019;8:e47365.
- 41. Palmer KL, Mashburn LM, Singh PK, Whiteley M. Cystic fibrosis sputum supports growth and cues key aspects of *Pseudomonas aeruginosa* physiology. *J Bacteriol* 2005;187:5267–5277.
- 42. Kvich L, Crone S, Christensen MH, Lima R, Alhede M, *et al*. Investigation of the mechanism and chemistry underlying *Staphylococcus aureus'* ability to Inhibit *Pseudomonas aeruginosa* growth *In Vitro*. *J Bacteriol* 2022;204:e0017422.
- 43. Zarrella TM, Khare A. Systematic identification of molecular mediators underlying sensing of *Staphylococcus aureus* by *Pseudomonas aeruginosa*. *Microbiology* 2021. DOI: 10.1101/2021.10.24.465352.
- <span id="page-13-3"></span>44. Turner KH, Wessel AK, Palmer GC, Murray JL, Whiteley M. Essential genome of *Pseudomonas aeruginosa* in cystic fibrosis sputum. *Proc Natl Acad Sci U S A* 2015;112:4110–4115.
- <span id="page-13-4"></span>45. Ruhluel D, O'Brien S, Fothergill JL, Neill DR. Development of liquid culture media mimicking the conditions of sinuses and lungs in cystic fibrosis and health. *F1000Res* 2022;11:1007.
- <span id="page-13-5"></span>46. Hoffman LR, Déziel E, D'Argenio DA, Lépine F, Emerson J, *et al*. Selection for *Staphylococcus aureus* small-colony variants due to growth in the presence of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 2006;103:19890–19895.
- <span id="page-13-6"></span>47. Halsey CR, Lei S, Wax JK, Lehman MK, Nuxoll AS, *et al*. Amino acid catabolism in *Staphylococcus aureus* and the function of carbon catabolite repression. *mBio* 2017;8:e01434-16.
- <span id="page-13-0"></span>48. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, *et al*. The involvement of cell-to-cell signals in the development of a bacterial biofilm. *Science* 1998;280:295–298.

Edited by: D. JV Beste and D. R Neill

**The Microbiology Society is a membership charity and not-for-profit publisher.**

**Your submissions to our titles support the community – ensuring that we continue to provide events, grants and professional development for microbiologists at all career stages.**

**Find out more and submit your article at microbiologyresearch.org**